Stelic Institute & Co..


Stelic’s lead compound is a synthetic double strand RNA oligonucleotide, a first-in-class molecule that inhibits carbohydrate sulfotransferase 15 (CHST15), which is involved in inflammation, fibrosis and cancer.

A Phase 2a study for the treatment of non-healing mucosal lesions in drug-refractory Ulcerative Colitis (UC) patients was recently completed.
Investigator Initiated Trial (IIT) studies with the patients with non-healing UC and Crohn’s Disease (CD) were also finished.